Compare Ascendis Pharma A/S (ASND) vs First Trust Cloud Computing ETF (SKYY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs First Trust Cloud Computing ETF — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while First Trust Cloud Computing ETF trades at $138.17. The key difference: Ascendis Pharma A/S is trading nearer its 52-week high, First Trust Cloud Computing ETF nearer its low. Which is the better fit depends on your goals.
| ASND | SKYY | |
|---|---|---|
Market Cap | $17.74B | — |
Sector | Health | — |
52-Week High | $277.18 | $155.17 |
52-Week Low | $163.32 | $104.16 |
Enterprise Value | $18.11B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
SKYY (First Trust Cloud Computing ETF) trades at $139.77, down 1.47% today, with strong technical momentum indicated by bullish moving averages. The ETF provides diversified exposure to cloud computing companies amid growing enterprise AI adoption. Recent news highlights continued institutional interest in technology ETFs and cloud computing sector strength.
The outlook remains positive as cloud computing benefits from enterprise digital transformation and AI spending acceleration. Key risks include sector concentration and technology volatility. Analyst coverage suggests the ETF offers strategic exposure to a high-growth technology segment with institutional-grade market positioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About First Trust Cloud Computing ETF
The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depositary receipts that comprise the index. The index is designed to track the performance of companies involved in the cloud computing industry.
Read more on SKYY →
